Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy Jg. 17; H. 1; S. 17
Hauptverfasser:	Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 28.01.2015 BioMed Central Ltd
Schlagworte:	Antigen presenting cells Antigens Antirheumatic agents Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Development and progression Drug therapy Health aspects Homeopathy Humans Interleukins Materia medica and therapeutics Medicine Medicine & Public Health Orthopedics Physiological aspects Proteasome Endopeptidase Complex - adverse effects Proteasome Inhibitors - therapeutic use Review Rheumatoid factor Rheumatology Systemic lupus erythematosus T cells Therapeutics Systemic Lupus Erythematosus Major Histocompatibility Complex Class Immune Effector Cell Bortezomib Rheumatoid Arthritis
ISSN:	1478-6354, 1478-6362, 1478-6354, 1478-6362
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!